A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
The purpose of this phase I/II study is to evaluate the safety and efficacy of Avutometinib (VS-6766) and Defactinib in combination with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Study ID: VS-6766-205
Trial Phase: Phase I/II
Trial Sponsor: Verastem, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Defactinib, Avutometinib